Dulaglutide and Type 2 Diabetes

WEBINAR: Tuesday 31 August 2021, 7.30 - 8.45 pm

In this webinar, Dr Ryan Paul diabetologist and endocrinologist overviews the role of dulaglutide, a subcutaneous once-weekly GLP-1 receptor agonist, in diabetes management.

Key topics include:

  • When and how to use dulaglutide to treat type 2 diabetes.
  • Advice on whether to choose funded dulaglutide or empagliflozin and when to consider switching between them.
  • When to advise patients to self-fund dulaglutide if possible.
  • How to reduce adverse effects of dulaglutide.
  • The potential for dulaglutide to get patients off insulin and the role of dulaglutide in prevention of cardiovascular disease.

As always, we'll answer as many questions as possible in the time we have.



Dr Ryan Paul

BHB MBChB (Auckland) FRACP, PhD

Ryan Paul is an endocrinologist and diabetologist at the Waikato District Health Board. He is active in research in his roles as a Senior Lecturer at the University of Waikato and as a Clinical Associate of the Maurice Wilkins Centre. He also has a key role in teaching as a member of the Royal Australasian College of Physicians (RACP) Training Committees and with Diabetes Nurse Prescribers in New Zealand, and was awarded the New Zealand Clinical Educator of the Year by the New Zealand Medical Council in 2019.

Ryan is also the current President of the New Zealand Society of Endocrinology (NZSE) and an Executive Member of the New Zealand Society for the Study of Diabetes (NZSSD). He recently convened the new NZSSD national guidance on the management of type 2 diabetes.


This webinar is supported by Lilly:

This presentation is intended for qualified health practitioners professional development and should not be relied upon for any other purpose. Any opinions offered are those of the presenter or other speaker and do not necessarily represent the views of Goodfellow Unit.

Sign into the website in order to register for this event.

Sign in